ArticleAdvanced biosystems2020
Nanochannel-Based Poration Drives Benign and Effective Nonviral Gene Delivery to Peripheral Nerve Tissue.
Article in Advanced biosystems, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Vasculogenic tissue nanotransfection accelerates functional recovery after peripheral nerve injury.Science advances · 2026Article
- Repurposing the skin to heal the body: Tissue Nanotransfection (TNT) as a therapeutic platform.Med-X · 2026Article
- Nanomaterial-Enhanced Conductive Hydrogels for Peripheral Nerve Repair: Biomimetic Design, Mechanisms, and Translational Challenges.International journal of nanomedicine · 2026Review
- Direct in vivo reprogramming to relieve tissue ischemia via induced vasculogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- Tissue nanotransfection and cellular reprogramming in regenerative medicine and antimicrobial dynamics.Frontiers in bioengineering and biotechnology · 2025Review
- FLI-1-driven regulation of endothelial cells in human diseases.Journal of translational medicine · 2024Review
- Quantification of Lymphangiogenesis in the Murine Lymphedema Tail Model Using Intravital Microscopy.Lymphatic research and biology · 2024Article
- Tissue Nanotransfection Silicon Chip and Related Electroporation-Based Technologies for In Vivo Tissue Reprogramming.Nanomaterials (Basel, Switzerland) · 2024Review
- Engineered Vasculogenic Extracellular Vesicles Drive Nonviral Direct Conversions of Human Dermal Fibroblasts into Induced Endothelial Cells and Improve Wound Closure.Advanced therapeutics · 2023Article
- Identification of a physiologic vasculogenic fibroblast state to achieve tissue repair.Nature communications · 2023Article
- Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss.NPJ Regenerative medicine · 2022Article
- Nanotechnology-Driven Cell-Based Therapies in Regenerative Medicine.The AAPS journal · 2022Review
- Designer Extracellular Vesicles Modulate Pro-Neuronal Cell Responses and Improve Intracranial Retention.Advanced healthcare materials · 2022Article
- Fabrication and use of silicon hollow-needle arrays to achieve tissue nanotransfection in mouse tissue in vivo.Nature protocols · 2021Review
- Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke.Science advances · 2021Article
- A Murine Tail Lymphedema Model.Journal of visualized experiments : JoVE · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
While gene and cell therapies have emerged as promising treatment strategies for various neurological conditions, heavy reliance on viral vectors can hamper widespread clinical implementation. Here, the use of tissue nanotransfection as a platform nanotechnology to drive nonviral gene delivery to nerve tissue via nanochannels, in an effective, controlled, and benign manner is explored. TNT facilitates plasmid DNA delivery to the sciatic nerve of mice in a voltage-dependent manner. Compared to standard bulk electroporation (BEP), impairment in toe-spread and pinprick response is not caused by TNT, and has limited to no impact on electrophysiological parameters. BEP, however, induces significant nerve damage and increases macrophage immunoreactivity. TNT is subsequently used to deliver vasculogenic cell therapies to crushed nerves via delivery of reprogramming factor genes Etv2, Foxc2, and Fli1 (EFF). The results indicate the TNT-based delivery of EFF in a sciatic nerve crush model leads to increased vascularity, reduced macrophage infiltration, and improved recovery in electrophysiological parameters compared to crushed nerves that are TNT-treated with sham/empty plasmids. Altogether, the results indicate that TNT can be a powerful platform nanotechnology for localized nonviral gene delivery to nerve tissue, in vivo, and the deployment of reprogramming-based cell therapies for nerve repair/regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.